



# News Now

John R. Kasich, Governor  
Tracy Plouck, Director

Jan. 9, 2015

## >>> RFP: Peer Services Transformation Transfer Initiative (TTI)

OhioMHAS has applied for a federal Transformation Transfer Initiative (TTI) funding opportunity from the Substance Abuse and Mental Health Services Administration. If awarded, TTI funds will be used to identify and adopt transformative activities to expand Ohio's Peer Service Initiative. OhioMHAS' goal is to develop a Peer Service Delivery Policy and Training Academy (PSDPTA). Objectives include: a) expanding the knowledge base of peer supporters, b) providing a clearinghouse for peer service information, c) enhancing statewide readiness and employment opportunities for peer supporters and d) hosting a two-day peer recovery and wellness conference.

OhioMHAS has released two Requests for Proposals, seeking to subcontract with individuals/businesses to: (1) develop webinars, and (2) recruit web resources, for the PSDPTA. Award of subcontracts under the RFPs are contingent upon OhioMHAS' receipt of an award from SAMHSA. Preference will be given to individuals with a lived experience of mental illness and/or substance use disorders, or businesses owned or operated by persons with lived experience. For complete details, view the following RFPs on the State Procurement [website](#): [MHA 15043](#) and [MHA15044](#).

Questions relating to the RFPs must be submitted online by 5:00 p.m. on Jan. 21, 2015. All questions and answers will be posted. You may not contact staff directly to discuss the RFPs. **Proposals are due no later than 2:00 p.m. on Jan. 23, 2015**, and must be submitted to: [OhioMHASBidOpportunity@mha.ohio.gov](mailto:OhioMHASBidOpportunity@mha.ohio.gov)

## >>> SAMHSA Issues Guidance on Use of Injectable Naltrexone

The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued new guidance on the clinical use of extended-release injectable naltrexone for treatment of opioid use disorder. [Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide](#) is based on a review of the current evidence on the effectiveness of available medications for the treatment of opioid use disorders, including a summary of the key differences between extended-release injectable naltrexone, methadone, and buprenorphine. The guidance provides key information on assessing the patient's need for treatment, and

initiating medication-assisted treatment (MAT). It also advises on how to monitor patient progress, adjust the treatment plan, and decide whether and when to end MAT.

### **In the News**

(1/9/15) *Columbus Dispatch* [Focus resources on young adults to cut poverty in Ohio, panel considers](#)

(1/8/15) *WKSU 89.7* [Tanisha's law would require mental health training for all Ohio police officers](#)

**Please share widely and encourage your colleagues to subscribe to *OhioMHAS eNews* on our [website](#). Also, be sure to join us on [Facebook](#), [Twitter](#), [YouTube](#) and [Flickr](#)!**